Board of Directors

The Board comprises a number of doctors who are specialists in their field and business and social sector leaders who kindly donate their time to help manage The Foundation.

The Board of Directors currently comprises of the following members:

Dr R Sauer (Chairman)

Rob joined as a Director of the National Foundation for Medical Research and Innovation in 2017 and was appointed as Chairman in 2018. He is qualified in law and accountancy, and was admitted as a solicitor of the Supreme Court of New South Wales in 1974, and as a CPA in 1980. He has a BA (majoring in French language) and an LLB from University of Sydney, a Master of Commerce from UNSW (majoring in accounting and financial management) and a Doctor of Business Administration from Charles Sturt University with a thesis on the subject of venture capital and angel investment in small technology-based companies. He is a consultant to the law firm DibbsBarker of which he was a partner between 1978 and 2008, apart from two years living and working in Tokyo with the law firm Anderson Mori. In 1986 Rob was appointed by the Federal Minister for Industry Technology and Commerce as the first Chairman of the R &D Tax Concession Committee to administer the 150% R&D tax concession scheme, and a member of the federal Industry Research and Development Board. In 1989, Rob was one of the founding shareholders and directors of ResMed, now listed on the New York Stock Exchange and ASX, presently the 25th largest company listed on ASX by market capitalisation. Rob was a member of the joint ASX and AusBiotech Committee which drafted the first Compliance Code for Listed Life Science companies. Rob was involved in the establishment of marine farming of salmon in Tasmania as the first chairman of Tassal Limited (1984-1990), and a director of Salmon Enterprises of Tasmania (1984-1988). He is Chairman of Myriax Pty Ltd (Echoview software), the world’s premier software for hydro-acoustic data processing used in fisheries research. Since 1995 he has also been a director of the Biopharm Australia Pty Ltd group involved in the development of sulphated polysaccharides in veterinary and human-use pharmaceuticals for the treatment of musculoskeletal and other diseases and disorders. Rob’s passions include a lifetime of attempting to master the game of golf, travel, food and wine. He has two children and three grandchildren, and lives about three months a year in Paris and the remainder at home in Sydney.


Mr J Harkness

Mr Harkness was a partner of KPMG for 24 years and National Executive Chairman for five years. After leaving KPMG in 2000, he has undertaken roles as a non executive director of listed and unlisted companies. Most recently, Mr Harkness was Chairman of Reliance Rail, and a Director of Goodman Group and Sinclair Knight Merz. He is currently Chairman of Charter Hall Retail Management Limited (director since August 2003), the management company of Charter Hall Retail REIT. John is a member of the Territorial Headquarters and Sydney Advisory Board of the Salvation Army. Mr Harkness joined the Board of Directors of the National Foundation for Medical Research and Innovation in 1984 and was appointed Chairman of the Foundation between 2000-2018. Mr Harkness is a Fellow of Chartered Accountants Australia and New Zealand and the Australian Institute of Company Directors.

John Dixon Hughes

Dr J Dixon Hughes OAM

John Dixon Hughes OAM has been a member of the Board of Directors and Research Advisory Committee since 1977. He became Chairman of the Research Advisory Committee in 2000. John is an active consultant general surgeon with over 55 years experience. From 1984 to 1996 John was the initial Chairman of the Medical Services Committee NSW, a statutory Committee to provide advice to the Government and the Ministry. He was the Administrator from 1996 – 2016. He is an Approved Medical Specialist for the Workers Compensation Commission NSW for disputes and appeals. John is a Fellow of the Royal Australasian College of Surgeons and was awarded the College Medal in 1990 and the NSW State Committee Merit Award in 2008 for distinguished service to surgery. John is also a foundation member of the Australian Association of Surgeons, Distinguished Councillor from 1982 and has served as President, Secretary and Councillor over many years. He is a Member of the Australian Medical Association and was appointed Fellow in 1985 and received the NSW President’s Award in1990, for distinguished services to medicine in NSW. John was formerly Chairman of Infection Control Advisory Group for NSW Health. He was also a Board Member for over 14 years and had served as Senior Vice President, Chairman of Medical Staff Council and Chairman of the Surgical Research and Ethics Committees at Sydney Hospital and was actively involved in surgical research. John was awarded an OAM in 2010 for services to medicine.

Dr E Saunders

Dr. Elaine Saunders is an award-winning businesswoman, audiologist and academic. Her accolades include being awarded BioMelbourne Network’s inaugural Women in Leadership Award in 2015, Asia’s Leading Woman in Healthcare in 2011, the Victorian Pearcey Entrepreneur Award in 2011, and the American Academy of Audiology’s Award for Achievement in Industry in 2010. Elaine was awarded the 2012 Melbourne Award for Contribution to Community by an Individual, and is one of Australia’s 100 most influential women (2015), and received the prestigious Clunies Ross Entrepreneur of the Year award (2016).

Dr K Hellestrand

Kevin Hellestrand has been a member of the Board of Directors in since 2001. Kevin Hellestrand has been in private practice as a Cardiologist and Cardiac Electrophysiologist for 25 years. He has been a co-author of more than 50 journal articles, reviews and book chapters. Kevin is a fellow of the Royal Australasian College of Physicians, American College of Cardiology, Cardiac Society of Australia and New Zealand, Heart Rhythm Society, European Society of Cardiology. He is also a member of the North Shore Heart Research Foundation.


A/Prof R Garrick AM

Raymond Garrick has been a member of the Board of Directors and Research Advisory Committee since 2002. He is Associate Professor of Medicine (Neurology) at the University of Notre Dame, Sydney Campus. Ray is a Neurologist with over 35 years experience. His areas of interest include neuro oncology, chronic pain, and multiple sclerosis. He is currently the Head of St Vincent ‘s & Mater Hospital sub-school of Notre Dame University Medical School. He is a fellow of the Royal Australasian College of Physicians and a member of the Australian & New Zealand Association of Neurologists. He is a fellow and faculty board member Faculty of Pain Medicine ANZCA, as well as Deputy Chairman of the Education Committee. Ray is also Senior investigator at Sydney Hospital/Sydney Eye Hospital for the RENEW clinical trial in optic neuritis. In 2015, Ray was recognised as a Member of the Order of Australia for significant service to medicine in the field of chronic pain management, and to medical education as an academic.


Mr A McGrath

Tony McGrath, has been Honorary Secretary of the Foundation since 1997. Tony is Co-Chairman of McGrathNicol which had its foundation on 1 July 2004. Prior to this Tony was the head of the Sydney Corporate Recovery division of KPMG. He has over 30 years of restructuring and insolvency experience. Tony has acted as Liquidator of the HIH Insurance Group which has been one of the largest failures in Australian corporate history. Other key engagements have included acting as Liquidator of the Pan Pharmaceuticals Group and the Voluntary Administration of the Henry Walker Eltin Group, Allco, Acting Trustee of Trio and Receiver of Banksia.  Tony is a Director of QBE Insurance (Australia) Ltd and is also a Commissioner of the Australian Rugby League.


Mr K Drewery

Keith Drewery joined the Board of the Foundation in 2010 Keith has worked for more than 30 years with wealth owners in professional services practices to help those families achieve financial goals and preserve wealth. He consults to wealthy families on issues of succession, legacy and philanthropy and also works closely with KPMG’s private enterprise division in Sydney in the development of their services to families and family offices. Originally working inside accounting firms as a tax specialist, Mr Drewery left the profession to work within funds management and between 2006 and 2011 he established and ran Myer Family Company’s Sydney office, Australia’s largest independent multi-family office. Through the last 15 years Mr Drewery has worked closely with founders and trustees of some of Australia’s most significant foundations and private ancillary funds. He consults widely to the not-for-profit sector.

Ashley Bates

Dr Ashley Bates

Dr Ashley Bates joined the Board and Research Advisory Committee of the Foundation in 2014 and is currently Director of Medical Technologies and Pharmaceuticals for AusIndustry’s Entrepreneur’s Programme. Ashley obtained his PhD from Heriot-Watt University, Edinburgh, Scotland and worked in the pharmaceutical industry for around 25 years. Starting as a research scientist he has worked in the UK and USA before moving to Australia. Ashley has held positions in new product development, business development at The Upjohn Company (now Pfizer) and GlaxoSmithKline. At GSK he was responsible building their collaborative research program and new product licencing activities. Ashley was the National Executive for Pharma and Biotech with the Manufacturing Excellence Taskforce Australia and served on a number of advisory panels and boards including academic, Cooperative Research Centres and industry associations. 

Alison Choy Flannigan

Ms A Choy Flannigan

Alison Choy Flannigan joined the Foundation as a Company Secretary in 2014. Alison has over 20 years of corporate and commercial experience and leads the Holman Webb Health, Aged Care and Life Sciences Team. Alison has been nominated by her peers as one of Australia’s best lawyers in the areas of health and aged care and has been recognised for this in Best Lawyers International and the Australian Financial Review. She was previously General Counsel of Ramsay Health Care Limited, as well as a partner of a major national law firm and has acted for a number of research related matters involving a number of public hospitals and eminent health and medical research institutes.

Prof A. Ian Smith

Professor Ian Smith joined NFMRI’s Board of Directors in 2017. He completed his first degree in Newcastle upon Tyne England and moved to Australia in 1984 to complete his PhD at Prince Henrys Institute Melbourne and Monash University. In 1991 Ian moved to the Baker Heart Research Institute and was Associate Director until his move to Monash University in 2004. Ian is currently Vice-Provost (Research & Research Infrastructure) and has responsibility for the oversight and management of the universities research alliances and research infrastructure as well as developing and implementing strategies to meet future university infrastructure needs in these areas. Professor Smith is an accomplished medical researcher and is recognized as a leader in his field. His research applies proteomics technologies to study the proteases involved in the generation and metabolism of peptide regulators involved in both brain and cardiovascular function. This research has resulted in over 250 publications and many patents. Ian receives regular invitations to speak at international meetings, many as a plenary speaker. Ian was a co-founder of a proteomics-based, publicly listed, biotechnology company and he continues to collaborate and consult widely with the pharmaceutical and biotechnology industry. Ian serves on six international editorial boards and over the years he has held office-bearing positions in a number of national and international societies and organisations, he has held and continues to hold, a variety of national and international senior government and non-government advisory board/committee memberships.





Looking beyond the research and considering translational needs when funding research. How well are your expectations, application and review processes, measures of success and funding strategy aligned with the next steps for translation?

Thank you for voting
You have already voted on this poll!
Please select an option!